Document is current

Article History

Accepted: 16 February 2025

First Online: 1 April 2025

Declarations

:

: This research was funded in part by the Canadian Institutes of Health Research (CIHR-IRSC), Foundation scheme grant number FDN-148413 and by the Université de Caen–Normandie “RECITAL International Partnership Laboratory” grant.

: É.B., R.L.B., T.E.H., P.S., and É.B.-O. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. É.B. is supported by scholarships from the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherche du Québec—Santé (FRQ-S). R.L.B. is the recipient of a CIHR doctoral scholarship. T.E.H. holds the Canadian Pacific Chair in Biotechnology. P.S. is the recipient of a Tier 1 Canada Research Chair in Neurophysiopharmacology of Chronic Pain and is a member of the FRQ-S-funded Québec Pain Research Network. É.B.-O. is the recipient of an Excellence Research Chair in Innovative Theranostics Approaches in Ovarian Cancers (THERANOVCA) funded by Région Normandie and cofunded by the European Union. The funders had no role in the design, writing of the manuscript, or in the decision to publish the manuscript.

: Not applicable.

: Not applicable.

: Not applicable.

: No new data were created or analyzed in this study. Press releases from Trevena and PharmNovo as well as minutes of FDA AADPAC meeting and “Second Cycle Review and Summary Basis for Approval” of oliceridine are available at .

: Not applicable.

: Conceptualization, É.B.-O.; writing–original draft preparation, É.B. and É.B.-O.; writing–review and editing, É.B, R.L.B., T.E.H., P.S., and É.B.-O.; visualization, É.B. and É.B.-O.; supervision, T.E.H., P.S., and É.B-O.; project administration, P.S. and É.B.-O; funding acquisition, P.S. and É.B.-O. All the authors have read and agreed to the published version of the manuscript.